Revolution goes adjuvant
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
HengRui goes pivotal in KRAS G12D
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Tango waltzes towards phase 3
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
ESMO 2025 – Incyte impresses in KRAS G12D
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Chia Tai keeps the TGF-β faith
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
Revolution could have a first-line pancreatic balancing act
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
